Trevena, Inc. (NASDAQ: TRVN), a clinical stage pharmaceutical company
focused on the discovery and development of G-protein coupled receptor
(GPCR) biased ligands, today announced that it will host a conference
call on Thursday, March 20, 2014 at 11:00 a.m. Eastern Time to discuss
corporate updates and financial results for the year ended December 31,
The call can be accessed by dialing (855) 465-0180 (U.S. and Canada) or
(484) 756-4313 (international), and entering passcode 14230881.
To access a live audio webcast of the presentation, please visit the
"Invetors" section at trevenainc.com.
The webcast will be recorded and available for replay on the company's
website for two weeks.
Trevena, Inc. is a clinical stage biopharmaceutical company that
discovers, develops and intends to commercialize therapeutics that use a
novel approach to target G protein coupled receptors, or GPCRs. Using
its proprietary product platform, Trevena has identified and advanced
three differentiated biased ligand product candidates into the clinic -
TRV027 to treat acute heart failure, TRV130 to treat moderate to severe
acute pain intravenously, and TRV734 to treat moderate to severe acute
and chronic pain orally. Trevena also plans to advance additional
product candidates in its portfolio, including a preclinical program
focused on central nervous system indications.
[ Back To NFVZone's Homepage ]